FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

ashington,	D.C.	20549	
------------	------	-------	--

OIVID APPRO	JVAL						
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* PACE GARY W				Suer Name and Ticker or Trading Symbol Cardiff Oncology, Inc. [CRDF] Date of Earliest Transaction (Month/Day/Year)								Relationship neck all appli X Director	cable)	Pers	on(s) to Iss 10% Ow Other (s	ner		
(Last)	(F	irst)	(Middle)		06/1	06/15/2023						below)	.0		below)			
C/O CARDIFF ONCOLOGY, INC.				4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable					
11055 FLINTKOTE AVENUE													Line) X Form filed by One Reporting Person					
(Street)	EGO C.	A	92121												iled by More		Ü	- 1
					Ru	Rule 10b5-1(c) Transaction Indication												
(City)	(S	tate)	(Zip)		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.								d to					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da				Execution Dat		Date,	e, Transaction Di Code (Instr. 5)		Dispose	ities Acquii d Of (D) (In		Benefici Owned	es Form ally (D) o Following (I) (II		m: Direct cor Indirect Enstr. 4)	7. Nature of Indirect Beneficial Ownership		
							Code	v	Amount (A) or (D)		r Price		orted saction(s) r. 3 and 4)			Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. B)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable an Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Sect (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	,	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable	Exp Dat	piration te	Title	Amount or Number of Shares					
Stock Options	\$1.59	06/15/2023			A		27,700		06/15/2024	06/	15/2033	Common Stock	27,700	\$0	117,274		D	

Explanation of Responses:

Remarks:

/s/ Gary Pace

06/20/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.